Pfizer will apply Triana Biomedicines’ target-first and proximity-first discovery platform to discover molecular glue degraders for unspecified “multiple” targets in oncology and several other disease ...

In this GEN webinar, Jeremy Tomlinson, PhD, will discuss the pathogenesis of MASLD, share examples from recent research that ...

The disruption of abnormal activity in the gut microbiome may increase our risk for neurological disease, research suggests.

Results suggest novel roles for LINE1 transposable elements that can be explored in the contexts of diseases, from ...

Researchers used gene therapy to convert harmful fatty acids into beneficial ones to help combat childhood obesity.

Investors shrugged as Illumina pressed its case for building on its longtime leadership in next-generation sequencing, ...

Both companies will focus on technology integration and marketing to ensure the successful adoption of the integrated solution.

Single-atom editing under mild conditions was achieved for heterocyclics, thanks to a new oxygen-to-nitrogen photocatalyst.

Researchers envision that any biology lab should be able to use the technique at low cost as it relies on standard, off-the-shelf chemicals and common equipment ...

Mark Munch, president of Bruker Nano Group, talks to GEN about Bruker’s reasons for acquiring Nanostring and their vision for ...

The company claims to have decoded human cell rejuvenation and identified potential gene targets for therapies that treat ...

MX2 wards off HIV-1 and herpes simplex virus-1 by assembling structures in the cell that lure and then trap them or even take ...